Center for Prevention and Control of Diseases

Chaoyang, China

Center for Prevention and Control of Diseases

Chaoyang, China
SEARCH FILTERS
Time filter
Source Type

Huang L.-R.,Center for Prevention and Control of Diseases
Chinese Journal of Biologicals | Year: 2017

Objective To evaluate the safety and immunogenicity of freeze-dried rabies vaccine (Vero cells) for human use in healthy population at ages of 10∼60 years. Methods A randomized (1 : 1), blind, positive-controlled trial involving 1 200 healthy subjects at 10∼60 years of age was conducted in Cenxi City and Cangwu County of Guangxi Zhuang Autonomous Region. The subjects were immunized with freeze-dried rabies vaccine (Vero cells) for human use on days 0, 3, 7, 14 and 28, using a commercial product of the same kind as control. Local and systemic adverse reactions were observed within 42 d, while serum samples were collected 14 and 42 d after the first immunization and determined for neutralizing antibody against rabies virus by rapid fluorescence focus inhibition test (RFFIT), based on which the GMC of antibody was calculated. Results A total of 1 199 subjects were observed for safety, of whom the systemic adverse reaction rates in trial (600 cases) and control (599 cases) groups were 12. 33% and 18. 03% respectively, which showed significant difference (P< 0. 05). The common symptom of systemic reactions was fever, of which the incidence rates in trial and control groups were 8. 00% and 13. 19% respectively. However, the local adverse reaction rates in trial and control groups were 5. 33% and 10. 52% respectively, which showed significant difference (P<0. 05). The symptoms of local adverse reactions were mainly pain, of which the incidence rates were 4. 17% and 8. 85% respectively. A total of 1 147 subjects were observed for immunogenicity, of whom the antibody positive conversion rates in trial (571 cases) and control (576 cases) groups were 100. 00% and 99. 83% respectively on day 14 and both 100. 00% on day 42 after the first immunization, which showed no significant difference (P> 0. 05). The GMCs of antibodies were 8. 94 and 7. 96 IU/ml on day 14, and 7. 26 and 15. 04 IU/ml on day 42 after the first immunization, respectively, which showed significant difference (P< 0. 05). Conclusion The freeze-dried rabies vaccine (Vero cells) for human use showed high safety and immunogenicity .


Yang L.-Q.,Center for Prevention and Control of Diseases | Li L.,Center for Prevention and Control of Diseases | Zhang N.,Center for Prevention and Control of Diseases | Jia B.,Center for Prevention and Control of Diseases | And 2 more authors.
Chinese Journal of Biologicals | Year: 2015

Objective To analyze the effect of two dose immunization schedule of varicella vaccine on the incidence of varicella in Chaoyang District, Beijing City, China. Methods After the implementation of two dose of immunization schedule of varicella vaccine, the data on varicella cases occurred in Chaoyang District during 2010 ∼ 2014 were analyzed by descriptive epidemiological method. Results The incidences in children at ages of 4 ∼ 12 years in 2013 and 2014 decreased by 73.41% than those in 2010 and 2011, while those in the populations at ages of less than 4 years and more than 12 years decreased by 18.75%. The ratio of incidence in children at ages of 4 ∼ 12 years decreased from 48.33% in 2010 and 2011 to 29.09% in 2013 and 2014. The sales volume of varicella vaccine in 2014 was 85 752 doses, which increased by 1.19 folds as compared with the mean sales volume in 2010 and 2011. The incidence showed a decreasing tendency with the increasing sales volume. The case number and outbreak of varicella in 2013 and 2014 decreased as compared with those in 2010 and 2011. More than 50% of the total cases had history of immunization, in which the proportion of breakthrough cases was higher than that of commom cases. Conclusion The two dose immunization schedule of varicella vaccine decreased the total incidence of varicella, of which the effect was superior to that of one dose immunization schedule.

Loading Center for Prevention and Control of Diseases collaborators
Loading Center for Prevention and Control of Diseases collaborators